The HCPLive rheumatoid arthritis page is a comprehensive resource for clinical news and insights on arthritis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for RA, and more.
May 29th 2024
In a new study, 16% of patients with RA and 22% with PsA had sleeping issues during the last week.
Despite Research, Utility of Calprotectin as Biomarker in Rheumatoid Arthritis Still Unclear
January 26th 2023A meta-analysis with data from more than 30 published articles provides an overview of associations between calprotectin levels and disease activity, treatment response, and inflammation among patients with rheumatoid arthritis.
Patients With Inflammatory Arthritis Feel Positive Toward Most Vaccinations
General practitioners and rheumatologists were viewed as sources of information that led to positive views toward vaccinations, while internet chatrooms, social media, and mainstream media were seen as sources of information that led to negative views.
Targeting the MK2 Pathway Reduces Tachyphylaxis Related to Rheumatoid Arthritis Therapy
January 24th 2023P38 mitogen-activated protein kinase (p38 MAPK) inhibitors have been a focal point for inflammatory diseases but the lack of efficacy in treating rheumatoid arthritis led to examination of the MK2 pathway.
Long-Term Cumulative Joint Inflammation Linked to Joint Damage Progression in Rheumatoid Arthritis
In the post-hoc analysis, an association between cumulative local joint swelling and progression of radiographic damage in the same joint was observed in patients with rheumatoid arthritis.
Adverse Reactions, Disease Activity Cited as Disease-Dependent Factors for Biosimilar Refusal
Disease-dependent factors, such as a history of adverse reactions to bio-originators and disease activity, influenced patients' acceptance of switching from a biologic to a biosimilar.
Patients with Rheumatoid Arthritis Satisfied with Switch to Adalimumab Biosimilar
Results of the study, which focused on patient-reported outcomes in addition to clinical measurements, mirror findings from other large-scale studies evaluating the safety and efficacy of biosimilars in patients with rheumatoid arthritis.